[
  {
    "objectID": "posts/Oncology/SCLC/staging.html",
    "href": "posts/Oncology/SCLC/staging.html",
    "title": "Staging",
    "section": "",
    "text": "The definition of small cell lung cancer is divided into two stages as shown in Table 1.\n\n\n\n\nTable 1: Definition of small cell lung cancer consists of two stages\n\n\n\n\n\n\n\n\n\nStage\nDescription\n\n\n\n\nLimited Stage\nStage I-III (T any, N any, M0) that can be safely treated with definitive radiation doses. Excludes T3-4 due to multiple lung nodules that are too extensive or tumor/nodal volume too large to be encompassed in a tolerable radiation plan.\n\n\nExtensive Stage\nStage IV (T any, N any, M1a/b/c), or T3-4 due to multiple lung nodules that are too extensive or tumor/nodal volume too large to be encompassed in a tolerable radiation plan.",
    "crumbs": [
      "Oncology",
      "SCLC",
      "Staging"
    ]
  },
  {
    "objectID": "posts/Oncology/NSCLC/staging.html",
    "href": "posts/Oncology/NSCLC/staging.html",
    "title": "Staging",
    "section": "",
    "text": "The definitions of T, N, and M staging in non-small cell lung cancer are shown in Table 1.\n\n\n\n\nTable 1: Definition of non-small cell lung cancer T, N, and M staging\n\n\n\n\n\n\n\n\n\nStage\nDescription\n\n\n\n\nTX\nPrimary tumor cannot be assessed, or tumor proven by the presence of malignant cells in sputum or bronchial washings but not visualized by imaging or bronchoscopy\n\n\nT0\nNo evidence of primary tumor\n\n\nTis\nCarcinoma in situ:  - Squamous cell carcinoma in situ (SCIS)  - Adenocarcinoma in situ (AIS): adenocarcinoma with pure lepidic pattern, ≤3 cm in greatest dimension\n\n\nT1\nTumor ≤3 cm in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (not in the main bronchus)\n\n\nT1mi\nMinimally invasive adenocarcinoma: adenocarcinoma (≤3 cm in greatest dimension) with a predominantly lepidic pattern and ≤5 mm invasion in greatest dimension\n\n\nT1a\nTumor ≤1 cm in greatest dimension. Includes superficial, spreading tumors of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus (rare)\n\n\nT1b\nTumor &gt;1 cm but ≤2 cm in greatest dimension\n\n\nT1c\nTumor &gt;2 cm but ≤3 cm in greatest dimension\n\n\nT2\nTumor &gt;3 cm but ≤5 cm or having any of the following features:  - Involves the main bronchus, regardless of distance to the carina, but without involvement of the carina  - Invades visceral pleura (PL1 or PL2)  - Associated with atelectasis or obstructive pneumonitis that extends to the hilar region, involving part or all of the lung\n\n\nT2a\nTumor &gt;3 cm but ≤4 cm in greatest dimension\n\n\nT2b\nTumor &gt;4 cm but ≤5 cm in greatest dimension\n\n\nT3\nTumor &gt;5 cm but ≤7 cm in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary\n\n\nT4\nTumor &gt;7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina; or separate tumor nodule(s) in an ipsilateral lobe different from that of the primary\n\n\nN\nRegional Lymph Nodes\n\n\nNX\nRegional lymph nodes cannot be assessed\n\n\nN0\nNo regional lymph node metastasis\n\n\nN1\nMetastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension\n\n\nN2\nMetastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)\n\n\nN3\nMetastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s)\n\n\nM\nDistant Metastasis\n\n\nM0\nNo distant metastasis\n\n\nM1\nDistant metastasis\n\n\nM1a\nSeparate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodules or malignant pleural or pericardial effusion\n\n\nM1b\nSingle extrathoracic metastasis in a single organ (including involvement of a single nonregional node)\n\n\nM1c\nMultiple extrathoracic metastases in a single organ or in multiple organs\n\n\n\n\n\n\n\nThe TNM stage grouping according to the 8th edition of the TNM classification of lung cancers is shown in Table 2.\n\n\n\n\nTable 2: TNM stage grouping according to the 8th edition\n\n\n\n\n\n\n\n\n\n\n\n\n\nT/M\nLabel\nN0\nN1\nN2\nN3\n\n\n\n\nT1\nT1a ≤ 1 cm\nIA1\nIIB\nIIIA\nIIIB\n\n\nT1b\n&gt; 1 to ≤ 2 cm\nIA2\nIIB\nIIIA\nIIIB\n\n\nT1c\n&gt; 2 to ≤ 3 cm\nIA3\nIIB\nIIIA\nIIIB\n\n\nT2\nT2a &gt; 3 to ≤ 4 cm\nIB\nIIB\nIIIA\nIIIB\n\n\nT2b\n&gt; 4 to ≤ 5 cm\nIIB\nIIB\nIIIA\nIIIB\n\n\nT3\n&gt; 5 to ≤ 7 cm\nIIB\nIIIA\nIIIB\nIIIC\n\n\nT3\nInvasion\nIIIA\nIIIA\nIIIB\nIIIC\n\n\nT3\nSatellite nodules\nIIIA\nIIIA\nIIIB\nIIIC\n\n\nT4\n&gt; 7 cm\nIIIA\nIIIA\nIIIB\nIIIC\n\n\nT4\nInvasion\nIIIA\nIIIA\nIIIB\nIIIC\n\n\nT4\nIpsilateral nodules\nIIIA\nIIIA\nIIIB\nIIIC\n\n\nM1\nM1a Contralateral nodules\nIVA\nIVA\nIVA\nIVA\n\n\n\nM1a Pleural, pericardial effusion\nIVA\nIVA\nIVA\nIVA\n\n\n\nM1b Single extrathoracic lesion\nIVA\nIVA\nIVA\nIVA\n\n\n\nM1c Multiple extrathoracic lesions\nIVB\nIVB\nIVB\nIVB\n\n\n\n\n\n\n\nThe TNM stage grouping according to the proposed 9th edition of the TNM classification of lung cancers is shown in Table 3.\n\n\n\n\nTable 3: TNM stage grouping according to the proposed 9th edition\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nT/M\nLabel\nN0\nN1\nN2a\nN2b\nN3\n\n\n\n\nT1\nT1a ≤ 1 cm\nIA1\nIIB\nIIIA\nIIIA\nIIIB\n\n\nT1b\n&gt; 1 to ≤ 2 cm\nIA2\nIIB\nIIIA\nIIIA\nIIIB\n\n\nT1c\n&gt; 2 to ≤ 3 cm\nIA3\nIIB\nIIIA\nIIIA\nIIIB\n\n\nT2\nT2a ≤ 4 cm\nIB\nIIIA\nIIIA\nIIIB\n\n\n\nT2b\n&gt; 4 to ≤ 5 cm\nIIB\nIIIA\nIIIA\nIIIB\n\n\n\nT3\n&gt; 5 to ≤ 7 cm\nIIB\nIIIA\nIIIB\n\n\n\n\nT3\nInvasion\nIIIA\nIIIA\nIIIB\nIIIC\n\n\n\nT3\nSatellite nodules\nIIIA\nIIIA\nIIIB\nIIIC\n\n\n\nT4\n&gt; 7 cm\nIIIA\nIIIA\nIIIB\nIIIC\n\n\n\nT4\nInvasion\nIIIA\nIIIA\nIIIB\nIIIC\n\n\n\nT4\nIpsilateral nodules\nIIIA\nIIIA\nIIIB\nIIIC\n\n\n\nM1\nM1a Contralateral nodules\nIVA\nIVA\nIVA\nIVA\n\n\n\n\nM1a Pleural, pericardial effusion\nIVA\nIVA\nIVA\nIVA\n\n\n\n\nM1b Single extra-thoracic lesion\nIVA\nIVA\nIVA\nIVA\n\n\n\n\nM1c1 Multiple extra-thoracic lesions in a single organ system\nIVB\nIVB\nIVB\nIVB\n\n\n\n\nM1c2 Multiple extra-thoracic lesions in multiple organ systems\nIVB\nIVB\nIVB\nIVB\n\n\n\n\n\n\n\n\nstage 1, 2는 수술 medically inoperable dearly stage NSCLC, SBRT",
    "crumbs": [
      "Oncology",
      "NSCLC",
      "Staging"
    ]
  },
  {
    "objectID": "posts/Oncology/Anal_Carcinoma/staging.html",
    "href": "posts/Oncology/Anal_Carcinoma/staging.html",
    "title": "Staging",
    "section": "",
    "text": "T Stage\nAJCC 8th Edition\nAJCC 9th Edition\n\n\n\n\nT1\nTumor ≤2 cm in greatest dimension\nTumor ≤2 cm in greatest dimension\n\n\nT2\nTumor &gt;2 cm but ≤5 cm in greatest dimension\nTumor &gt;2 cm but ≤5 cm in greatest dimension\n\n\nT3\nTumor &gt;5 cm in greatest dimension\nTumor &gt;5 cm in greatest dimension\n\n\nT4\nTumor of any size invading adjacent organ(s) (e.g., vagina, urethra, bladder)\nTumor of any size invading adjacent organ(s) (e.g., vagina, urethra, bladder)\n\n\nT4a\nNot applicable\nTumor involving the skin of the perianal area\n\n\nT4b\nNot applicable\nTumor invading adjacent structures (vagina, urethra, bladder, etc.)\n\n\n\nNote: The main difference between the AJCC 8th and 9th Editions is the subdivision of T4 into T4a and T4b in the 9th Edition, which provides a more detailed categorization for advanced local disease.",
    "crumbs": [
      "Oncology",
      "Anal Carcinoma",
      "Staging"
    ]
  },
  {
    "objectID": "posts/Oncology/Anal_Carcinoma/staging.html#t-stage",
    "href": "posts/Oncology/Anal_Carcinoma/staging.html#t-stage",
    "title": "Staging",
    "section": "",
    "text": "T Stage\nAJCC 8th Edition\nAJCC 9th Edition\n\n\n\n\nT1\nTumor ≤2 cm in greatest dimension\nTumor ≤2 cm in greatest dimension\n\n\nT2\nTumor &gt;2 cm but ≤5 cm in greatest dimension\nTumor &gt;2 cm but ≤5 cm in greatest dimension\n\n\nT3\nTumor &gt;5 cm in greatest dimension\nTumor &gt;5 cm in greatest dimension\n\n\nT4\nTumor of any size invading adjacent organ(s) (e.g., vagina, urethra, bladder)\nTumor of any size invading adjacent organ(s) (e.g., vagina, urethra, bladder)\n\n\nT4a\nNot applicable\nTumor involving the skin of the perianal area\n\n\nT4b\nNot applicable\nTumor invading adjacent structures (vagina, urethra, bladder, etc.)\n\n\n\nNote: The main difference between the AJCC 8th and 9th Editions is the subdivision of T4 into T4a and T4b in the 9th Edition, which provides a more detailed categorization for advanced local disease.",
    "crumbs": [
      "Oncology",
      "Anal Carcinoma",
      "Staging"
    ]
  },
  {
    "objectID": "posts/Oncology/Anal_Carcinoma/staging.html#n-stage",
    "href": "posts/Oncology/Anal_Carcinoma/staging.html#n-stage",
    "title": "Staging",
    "section": "N stage",
    "text": "N stage\n\n\n\n\n\n\n\n\nN Stage\n8th Edition\n9th Edition\n\n\n\n\nN0\nNo regional lymph node metastasis\nNo regional lymph node metastasis\n\n\nN1a\nMetastasis in inguinal, mesorectal, or internal iliac lymph nodes\nMetastasisTumor involvement of inguinal, mesorectal, superior rectal, internal iliac, or obturator lymph node(s)\n\n\nN1b\nMetastasis in external iliac lymph nodes (rare, but included when associated with inguinal or internal iliac)\nMetastasis in external iliac lymph nodes (same as 8th edition)\n\n\nN1c\nMetastasis in multiple regional lymph nodes (combination of N1a and N1b sites)\nMetastasis in multiple regional lymph nodes (combination of N1a and N1b sites)\n\n\nChanges\n-\nClarification in definitions, improved staging accuracy",
    "crumbs": [
      "Oncology",
      "Anal Carcinoma",
      "Staging"
    ]
  },
  {
    "objectID": "posts/Oncology/Anal_Carcinoma/staging.html#m-stage",
    "href": "posts/Oncology/Anal_Carcinoma/staging.html#m-stage",
    "title": "Staging",
    "section": "M stage",
    "text": "M stage",
    "crumbs": [
      "Oncology",
      "Anal Carcinoma",
      "Staging"
    ]
  },
  {
    "objectID": "posts/IT/Rasberry_Pi/setup.html",
    "href": "posts/IT/Rasberry_Pi/setup.html",
    "title": "setup",
    "section": "",
    "text": "Figure 1 는 2024년 11월 16일 현재 우리집 Rassberry Pi에 사용중인 마이크로 SD (Secure Digital) 카드이다. 초기의 FAT16파일시스템을 사용하여 용량이 2 GB로 제한되었으나 이 제품은 FAT32파일시스템을 사용한 SDHC (Secure Digial High Capacity) 제품이다. Class라 부르며 기록을 할 수 있는 속도를 우측이 비어있는 원안에 표시를 한다. 우리집 것은 10이 있으며 이는 기록속도가 초당 10 MB라는 의미이다.\n요약하자면\n\nFAT32 파일시스템\n32 GB 저장용량\nClass 10 (= 초당 10 MB) 기록속도\n\n\n\n\n\n\n\nFigure 1: 마이크로 SD 카드",
    "crumbs": [
      "IT",
      "Rasberry Pi",
      "setup"
    ]
  },
  {
    "objectID": "posts/IT/Rasberry_Pi/setup.html#마이크로-sd-카드",
    "href": "posts/IT/Rasberry_Pi/setup.html#마이크로-sd-카드",
    "title": "setup",
    "section": "",
    "text": "Figure 1 는 2024년 11월 16일 현재 우리집 Rassberry Pi에 사용중인 마이크로 SD (Secure Digital) 카드이다. 초기의 FAT16파일시스템을 사용하여 용량이 2 GB로 제한되었으나 이 제품은 FAT32파일시스템을 사용한 SDHC (Secure Digial High Capacity) 제품이다. Class라 부르며 기록을 할 수 있는 속도를 우측이 비어있는 원안에 표시를 한다. 우리집 것은 10이 있으며 이는 기록속도가 초당 10 MB라는 의미이다.\n요약하자면\n\nFAT32 파일시스템\n32 GB 저장용량\nClass 10 (= 초당 10 MB) 기록속도\n\n\n\n\n\n\n\nFigure 1: 마이크로 SD 카드",
    "crumbs": [
      "IT",
      "Rasberry Pi",
      "setup"
    ]
  },
  {
    "objectID": "posts/IT/Rasberry_Pi/setup.html#raspberry-pi-setup",
    "href": "posts/IT/Rasberry_Pi/setup.html#raspberry-pi-setup",
    "title": "setup",
    "section": "Raspberry Pi setup",
    "text": "Raspberry Pi setup\n\n설치파일 다운로드\n공식사이트에서 라즈베리파이 설치 이미지파일을 다운로드 받는다 (https://www.raspberrypi.com/software/). 2024년 11월 16일 현재 원도우용 최신 설치이미지파일은 imager_1.8.5.exe이다.\n\n\nSD카드에 OS설치\n이미지설치파일을 실행하여\n\n운영체제를 선택하고…\nCustomizing OS에서 아래의 사항들을 선택하고 진행한다.\n\nEnable SSH checkbox 선택하여 진행하면\n\npi user에 대한 password 설정해야 하고\n\n-   password를 default `raspberry`로 진행한다면 이후 변경해야 함\nConfigure Wifi 선택하여 진행하면\n\nSSID: ??_ ????????????\nPassword: ??????????\n\n\n설치가 완료가 완료되면 사용 가능한 상태가 된다.\n\n\n\nSSH 접속\n\nAndroid에서는 SSH 클라이언트를 설치하여 접속한다. 대표적인 SSH 클라이언트는 다음과 같다.\n\nTermius: Android에서도 사용 가능하며 플랫폼 간 동기화 지원.\nJuiceSSH: 인기 있는 Android SSH 클라이언트, 무료 및 유료 플랜 제공.\nConnectBot: 오픈소스이며 가벼운 SSH 클라이언트.\n\nRaspberry Pi의 IP를 알기위해 Android 용 Network Discovery가 추천된다.\nWindows에서는 PuTTY를 사용한다.\n\n\n\nVNC 접속\n\nsudo raspi-config\n\nVNC enable을 선택하여 활성화한다. 해상도 설정\n안드로이드용 AVNC를 설치하여 접속",
    "crumbs": [
      "IT",
      "Rasberry Pi",
      "setup"
    ]
  },
  {
    "objectID": "posts/about.html",
    "href": "posts/about.html",
    "title": "사이트사용법",
    "section": "",
    "text": "이 웹사이트는 저자가 공부한 것을 정리한 것입니다.\ntop tiitle 메뉴에 속하는 sidebar 메뉴에 따라 각 웹페이지가 배정되어 있읍니다. 그러면서도 각 페이지들은 모두 블로그에서도 보이게 됩니다. 블로그는 최종 수정된 날짜의 역순이 기본값입니다.\n\n이는 체계적인 메뉴의 분류에 따라서 해당 페이지를 찾아갈 수도 있지만\n등록된 날짜순이나\n수정된 날짜순으로도 내용을 확인할 수 있음을 의미합니다.\n\n댓글 기능은 guthub에 가입해야 가능합니다."
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "블로그",
    "section": "",
    "text": "Anatomy\n\n\n\n\n\n\nanatomy\n\n\n\nanatomy 공부한 것을 정리\n\n\n\n\n\nNov 21, 2024\n\n\nBenKorea\n\n\n\n\n\n\n\n\n\n\n\n\nPelvis\n\n\n\n\n\n\npelvis\n\n\nlympn node\n\n\nstation\n\n\n\npelic LN stataion definition에 대해 정리할 예정\n\n\n\n\n\nNov 21, 2024\n\n\nBenKorea\n\n\n\n\n\n\n\n\n\n\n\n\nStaging\n\n\n\n\n\n\nAnal Carcinoma\n\n\nstaging\n\n\nAJCC 8th\n\n\nAJCC 9th\n\n\n\nAnal Carcinoma AJCC 8th & AJCC 9th staging 비교\n\n\n\n\n\nNov 21, 2024\n\n\nBenKorea\n\n\n\n\n\n\n\n\n\n\n\n\nOncology\n\n\n\n\n\n\noncology\n\n\n\n\n\n\n\n\n\nNov 21, 2024\n\n\nBenKorea\n\n\n\n\n\n\n\n\n\n\n\n\nStaging\n\n\n\n\n\n\nNSCLC\n\n\nstaging\n\n\n\nNSCLC AJCC 8th editiopn (2017)\n\n\n\n\n\nNov 18, 2024\n\n\nBenKorea\n\n\n\n\n\n\n\n\n\n\n\n\nIT\n\n\n\n\n\n\nIT\n\n\n\n구축한 & 구축하고자 하는 시스템에 대한 조사 및 설명\n\n\n\n\n\nNov 16, 2024\n\n\nBenKorea\n\n\n\n\n\n\n\n\n\n\n\n\nsetup\n\n\n\n\n\n\nRasberry pi\n\n\nsetup\n\n\n\n라즈베리파이 설치\n\n\n\n\n\nNov 16, 2024\n\n\nBenKorea\n\n\n\n\n\n\n\n\n\n\n\n\n구성 예시\n\n\n\n\n\n\nsilent PC\n\n\nsetup\n\n\n\n무소음PC의 구성 예시\n\n\n\n\n\nNov 16, 2024\n\n\nBenKorea\n\n\n\n\n\n\n\n\n\n\n\n\nStaging\n\n\n\n\n\n\nProstate cancer\n\n\nstaging\n\n\nAJCC 8th\n\n\n\nProstate cancer AJCC 8th editiopn (2017)\n\n\n\n\n\nOct 14, 2024\n\n\nBenKorea\n\n\n\n\n\n\n\n\n\n\n\n\nStaging\n\n\n\n\n\n\nSCLC\n\n\nstaging\n\n\nAJCC 8th\n\n\n\nSCLC AJCC 8th editiopn (2017)\n\n\n\n\n\nOct 14, 2024\n\n\nBenKorea\n\n\n\n\n\n\n\n\n\n\n\n\n사이트사용법\n\n\n\n\n\n\n\n\n\n\n\nJan 1, 2024\n\n\nBenkorea\n\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "posts/IT/silent_pc/silent_pc.html",
    "href": "posts/IT/silent_pc/silent_pc.html",
    "title": "구성 예시",
    "section": "",
    "text": "목표: 팬리스(Fanless) 시스템 구축\n중점 요소:\n\nCPU, PSU, 저장 장치에서 소음 발생 최소화\n공기 흐름이 원활한 매쉬형 케이스 선택\n140mm 팬을 저RPM으로 설정하여 발열 문제 해결",
    "crumbs": [
      "IT",
      "무소음 PC",
      "구성 예시"
    ]
  },
  {
    "objectID": "posts/IT/silent_pc/silent_pc.html#cpu-선택",
    "href": "posts/IT/silent_pc/silent_pc.html#cpu-선택",
    "title": "구성 예시",
    "section": "2.1 CPU 선택",
    "text": "2.1 CPU 선택\n\n비교 모델: Intel Core i3-13100T vs Intel Core i5-9500\n최종 선택: Intel Core i3-13100T (35W 저전력)\n이유:\n\n저전력(35W)으로 발열이 적음\n4코어 8스레드로 팬리스 환경에서도 성능 유지 가능\n최신 DDR5 및 PCIe 5.0 지원 → 확장성 높음",
    "crumbs": [
      "IT",
      "무소음 PC",
      "구성 예시"
    ]
  },
  {
    "objectID": "posts/IT/silent_pc/silent_pc.html#cpu-쿨러-선택",
    "href": "posts/IT/silent_pc/silent_pc.html#cpu-쿨러-선택",
    "title": "구성 예시",
    "section": "2.2 CPU 쿨러 선택",
    "text": "2.2 CPU 쿨러 선택\n\n비교 모델: NOFAN 아이스파이프 vs Noctua NH-P1\n최종 선택: NOFAN 아이스파이프\n이유:\n\n팬 없이도 80W 이하 CPU 냉각 가능\n크기가 작아 케이스 내부 공간 활용성이 높음\n저소음 시스템에 최적",
    "crumbs": [
      "IT",
      "무소음 PC",
      "구성 예시"
    ]
  },
  {
    "objectID": "posts/IT/silent_pc/silent_pc.html#마더보드-선택",
    "href": "posts/IT/silent_pc/silent_pc.html#마더보드-선택",
    "title": "구성 예시",
    "section": "2.3 마더보드 선택",
    "text": "2.3 마더보드 선택\n\n비교 모델: ASRock B760M-HDV/M.2 (M-ATX) vs ATX 보드\n최종 선택: ASRock B760M-HDV/M.2 (M-ATX)\n이유:\n\nPCIe 5.0 및 최신 DDR5 지원\nM-ATX 폼팩터로 공간 절약 가능\n팬리스 시스템에서 추가 확장이 필요하지 않음",
    "crumbs": [
      "IT",
      "무소음 PC",
      "구성 예시"
    ]
  },
  {
    "objectID": "posts/IT/silent_pc/silent_pc.html#스토리지-선택",
    "href": "posts/IT/silent_pc/silent_pc.html#스토리지-선택",
    "title": "구성 예시",
    "section": "2.4 스토리지 선택",
    "text": "2.4 스토리지 선택\n\n비교 모델: PCIe 3.0 vs PCIe 4.0 NVMe SSD\n최종 선택: Crucial P3 1TB PCIe 3.0 NVMe SSD\n이유:\n\nPCIe 4.0 대비 발열이 적음\n무소음 유지 가능 (HDD 사용 X)\n충분한 속도 제공 (3500MB/s)",
    "crumbs": [
      "IT",
      "무소음 PC",
      "구성 예시"
    ]
  },
  {
    "objectID": "posts/IT/silent_pc/silent_pc.html#케이스-선택",
    "href": "posts/IT/silent_pc/silent_pc.html#케이스-선택",
    "title": "구성 예시",
    "section": "2.5 케이스 선택",
    "text": "2.5 케이스 선택\n\n비교 모델: JONSBO UMX3 vs Fractal Meshify 2 XL vs 3RSYS L600 Quiet\n최종 선택: 3RSYS L600 Quiet (미들타워, 140mm 팬 4개 포함)\n이유:\n\n기본적으로 저소음 팬 제공\n메쉬형 설계로 공기 흐름 극대화\n강화유리 패널로 디자인 유지 가능",
    "crumbs": [
      "IT",
      "무소음 PC",
      "구성 예시"
    ]
  },
  {
    "objectID": "posts/IT/silent_pc/silent_pc.html#파워-서플라이psu-선택",
    "href": "posts/IT/silent_pc/silent_pc.html#파워-서플라이psu-선택",
    "title": "구성 예시",
    "section": "2.6 파워 서플라이(PSU) 선택",
    "text": "2.6 파워 서플라이(PSU) 선택\n\n비교 모델: Seasonic Prime Fanless 500W vs 일반 PSU\n최종 선택: Seasonic Prime Fanless 500W (Platinum 인증)\n이유:\n\n완전 팬리스 설계로 무소음 유지\n고효율 (80+ Platinum)로 발열 최소화\n장기간 안정적인 전력 공급 가능",
    "crumbs": [
      "IT",
      "무소음 PC",
      "구성 예시"
    ]
  },
  {
    "objectID": "posts/IT/silent_pc/silent_pc.html#냉각-솔루션-최적화-팬-설정",
    "href": "posts/IT/silent_pc/silent_pc.html#냉각-솔루션-최적화-팬-설정",
    "title": "구성 예시",
    "section": "2.7 냉각 솔루션 최적화 (팬 설정)",
    "text": "2.7 냉각 솔루션 최적화 (팬 설정)\n\n비교: 120mm 팬 vs 140mm 팬\n최종 선택: 140mm 팬 사용 (기본 장착, 저RPM 설정)\n이유:\n\n600~800RPM 저속 설정으로 무소음 유지 가능\n120mm 팬 대비 저RPM에서도 동일한 풍량 제공\nBIOS에서 PWM 모드 설정하여 자동 속도 조절 가능",
    "crumbs": [
      "IT",
      "무소음 PC",
      "구성 예시"
    ]
  },
  {
    "objectID": "posts/Oncology/prostate/staging.html",
    "href": "posts/Oncology/prostate/staging.html",
    "title": "Staging",
    "section": "",
    "text": "Table 1: Definition of clinical stages\n\n\n\n\n\n\n\n\n\ncT\nDescription\n\n\n\n\nTX\nPrimary tumor cannot be assessed\n\n\nT0\nNo evidence of primary tumor\n\n\nT1\nClinically inapparent tumor that is not palpable\n\n\nT1a\nTumor incidental histologic finding in 5% or less of tissue resected\n\n\nT1b\nTumor incidental histologic finding in more than 5% of tissue resected\n\n\nT1c\nTumor identified by needle biopsy found in one or both sides, but not palpable\n\n\nT2\nTumor is palpable and confined within prostate\n\n\nT2a\nTumor involves one-half of one side or less\n\n\nT2b\nTumor involves more than one-half of one side but not both sides\n\n\nT2c\nTumor involves both sides\n\n\nT3\nExtraprostatic tumor that is not fixed or does not invade adjacent structures\n\n\nT3a\nExtraprostatic extension (unilateral or bilateral)\n\n\nT3b\nTumor invades seminal vesicle(s)\n\n\nT4\nTumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall"
  },
  {
    "objectID": "posts/Oncology/prostate/staging.html#clinical-t-staging",
    "href": "posts/Oncology/prostate/staging.html#clinical-t-staging",
    "title": "Staging",
    "section": "",
    "text": "Table 1: Definition of clinical stages\n\n\n\n\n\n\n\n\n\ncT\nDescription\n\n\n\n\nTX\nPrimary tumor cannot be assessed\n\n\nT0\nNo evidence of primary tumor\n\n\nT1\nClinically inapparent tumor that is not palpable\n\n\nT1a\nTumor incidental histologic finding in 5% or less of tissue resected\n\n\nT1b\nTumor incidental histologic finding in more than 5% of tissue resected\n\n\nT1c\nTumor identified by needle biopsy found in one or both sides, but not palpable\n\n\nT2\nTumor is palpable and confined within prostate\n\n\nT2a\nTumor involves one-half of one side or less\n\n\nT2b\nTumor involves more than one-half of one side but not both sides\n\n\nT2c\nTumor involves both sides\n\n\nT3\nExtraprostatic tumor that is not fixed or does not invade adjacent structures\n\n\nT3a\nExtraprostatic extension (unilateral or bilateral)\n\n\nT3b\nTumor invades seminal vesicle(s)\n\n\nT4\nTumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall"
  },
  {
    "objectID": "posts/Oncology/prostate/staging.html#pathologic-t-staging",
    "href": "posts/Oncology/prostate/staging.html#pathologic-t-staging",
    "title": "Staging",
    "section": "Pathologic T Staging",
    "text": "Pathologic T Staging\n\n\n\n\nTable 2: Definition of pathologic T stages\n\n\n\n\n\n\n\n\n\npT\nDescription\n\n\n\n\nT2\nOrgan confined\n\n\nT3\nExtraprostatic extension\n\n\nT3a\nExtraprostatic extension (unilateral or bilateral) or microscopic invasion of bladder neck\n\n\nT3b\nTumor invades seminal vesicle(s)\n\n\nT4\nTumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall\n\n\n\n\n\n\n\nNote: There is no pathological T1\nNote: Positive surgical margin should be indicated by an R1 descriptor, indicating residual microscopic disease."
  },
  {
    "objectID": "posts/Oncology/Prostate_Cancer/staging.html",
    "href": "posts/Oncology/Prostate_Cancer/staging.html",
    "title": "Staging",
    "section": "",
    "text": "Table 1: Definition of clinical stages\n\n\n\n\n\n\n\n\n\ncT\nDescription\n\n\n\n\nTX\nPrimary tumor cannot be assessed\n\n\nT0\nNo evidence of primary tumor\n\n\nT1\nClinically inapparent tumor that is not palpable\n\n\nT1a\nTumor incidental histologic finding in 5% or less of tissue resected\n\n\nT1b\nTumor incidental histologic finding in more than 5% of tissue resected\n\n\nT1c\nTumor identified by needle biopsy found in one or both sides, but not palpable\n\n\nT2\nTumor is palpable and confined within prostate\n\n\nT2a\nTumor involves one-half of one side or less\n\n\nT2b\nTumor involves more than one-half of one side but not both sides\n\n\nT2c\nTumor involves both sides\n\n\nT3\nExtraprostatic tumor that is not fixed or does not invade adjacent structures\n\n\nT3a\nExtraprostatic extension (unilateral or bilateral)\n\n\nT3b\nTumor invades seminal vesicle(s)\n\n\nT4\nTumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall",
    "crumbs": [
      "Oncology",
      "Prostate Cancer",
      "Staging"
    ]
  },
  {
    "objectID": "posts/Oncology/Prostate_Cancer/staging.html#clinical-t-staging",
    "href": "posts/Oncology/Prostate_Cancer/staging.html#clinical-t-staging",
    "title": "Staging",
    "section": "",
    "text": "Table 1: Definition of clinical stages\n\n\n\n\n\n\n\n\n\ncT\nDescription\n\n\n\n\nTX\nPrimary tumor cannot be assessed\n\n\nT0\nNo evidence of primary tumor\n\n\nT1\nClinically inapparent tumor that is not palpable\n\n\nT1a\nTumor incidental histologic finding in 5% or less of tissue resected\n\n\nT1b\nTumor incidental histologic finding in more than 5% of tissue resected\n\n\nT1c\nTumor identified by needle biopsy found in one or both sides, but not palpable\n\n\nT2\nTumor is palpable and confined within prostate\n\n\nT2a\nTumor involves one-half of one side or less\n\n\nT2b\nTumor involves more than one-half of one side but not both sides\n\n\nT2c\nTumor involves both sides\n\n\nT3\nExtraprostatic tumor that is not fixed or does not invade adjacent structures\n\n\nT3a\nExtraprostatic extension (unilateral or bilateral)\n\n\nT3b\nTumor invades seminal vesicle(s)\n\n\nT4\nTumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall",
    "crumbs": [
      "Oncology",
      "Prostate Cancer",
      "Staging"
    ]
  },
  {
    "objectID": "posts/Oncology/Prostate_Cancer/staging.html#pathologic-t-staging",
    "href": "posts/Oncology/Prostate_Cancer/staging.html#pathologic-t-staging",
    "title": "Staging",
    "section": "Pathologic T Staging",
    "text": "Pathologic T Staging\n\n\n\n\nTable 2: Definition of pathologic T stages\n\n\n\n\n\n\n\n\n\npT\nDescription\n\n\n\n\nT2\nOrgan confined\n\n\nT3\nExtraprostatic extension\n\n\nT3a\nExtraprostatic extension (unilateral or bilateral) or microscopic invasion of bladder neck\n\n\nT3b\nTumor invades seminal vesicle(s)\n\n\nT4\nTumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall\n\n\n\n\n\n\n\nNote: There is no pathological T1\nNote: Positive surgical margin should be indicated by an R1 descriptor, indicating residual microscopic disease.",
    "crumbs": [
      "Oncology",
      "Prostate Cancer",
      "Staging"
    ]
  }
]